A bivalent ZHER2:4 generated by Steffen et al. exhibited stronger binding between HER2 and (ZHER2:4)2, as well as increased internalization and cell retention compared to those of the monovalent affibody, and was evaluated in terms of tumor targeting in mice [36,37]. Here, ERBB2 is linked to neoplasm.